Amr Salahieh
Chair & Acting CEO
Amr is a seasoned medical device entrepreneur with over 30 years of healthcare experience. He is the founder and CEO of Shifamed LLC, a successful and well- established medical innovation hub headquartered in the heart of Silicon Valley. Legacy portfolio companies that Amr has held a leadership role in include Embolic Protection Inc. (acquired by Boston Scientific, 2001), Sadra Medical (acquired by Boston Scientific, 2011), Maya Medical (acquired by Covidien, 2012), Kalila Medical (acquired by Abbott, 2016), Apama Medical (acquired by Boston Scientific, 2017) and NuVera Medical (acquired by Biosense Webster, a Johnson & Johnson company, 2020).
Shifamed and its dedicated management team have raised over $800M to date for its portfolio companies. Current portfolio companies include five focused in cardiovascular, two in ophthalmology and one enterprise software company. All portfolio companies are founded within Shifamed, with Amr serving as the Chairman of the Board. Each company is an independent Delaware entity led by an experienced CEO or General Manager, with a focused team and strategically structured for rapid integration upon acquisition. To date, Shifamed has grown to over 350 employees across its nine- building campus and over 50 OUS employees.
Amr is the inventor or co-inventor on over 400 issued and pending patent applications worldwide. He holds a B.S. in Biomedical Engineering and a B.S. in Electrical Engineering from Case Western Reserve University.
Amr is a seasoned medical device entrepreneur with over 30 years of healthcare experience. He is the founder and CEO of Shifamed LLC, a successful and well- established medical innovation hub headquartered in the heart of Silicon Valley. Legacy portfolio companies that Amr has held a leadership role in include Embolic Protection Inc. (acquired by Boston Scientific, 2001), Sadra Medical (acquired by Boston Scientific, 2011), Maya Medical (acquired by Covidien, 2012), Kalila Medical (acquired by Abbott, 2016), Apama Medical (acquired by Boston Scientific, 2017) and NuVera Medical (acquired by Biosense Webster, a Johnson & Johnson company, 2020).
Shifamed and its dedicated management team have raised over $800M to date for its portfolio companies. Current portfolio companies include five focused in cardiovascular, two in ophthalmology and one enterprise software company. All portfolio companies are founded within Shifamed, with Amr serving as the Chairman of the Board. Each company is an independent Delaware entity led by an experienced CEO or General Manager, with a focused team and strategically structured for rapid integration upon acquisition. To date, Shifamed has grown to over 350 employees across its nine- building campus and over 50 OUS employees.
Amr is the inventor or co-inventor on over 400 issued and pending patent applications worldwide. He holds a B.S. in Biomedical Engineering and a B.S. in Electrical Engineering from Case Western Reserve University.
